Joe Fox Named President of Beckman Coulter Life Sciences

 Beckman Coulter Life Sciences has appointed Joe Fox, Ph.D., as president, effective immediately.
 
Dr. Fox joins Beckman Coulter Life Sciences from SCIEX, a Danaher Corporation operating company, where he held positions of increasing responsibility over the past 13 years, most recently serving as president.
 
“Joe is a proven leader with a strong track record of successfully growing businesses and building diverse, inclusive and engaged teams in the life science and clinical industries,” said Greg Milosevich, vice president and group executive of the Danaher Life Sciences Innovations Group. “He understands our strategy, culture of our Danaher Business System (DBS), and has a strong commitment to customer excellence. Joe will help Beckman Coulter Life Sciences continue to deliver meaningful innovation while developing and attracting top talent.”
 
Dr. Fox will lead a global team of more than 3,300 associates, driving product and service innovation to deliver workflow solutions in areas including centrifugation, flow cytometry, genomics, particle analysis, and liquid handling. He will also champion the Beckman Coulter Life Sciences commitment to sustainability which includes further integrating sustainability into operations, products, and packaging.
 
Prior to joining SCIEX, Dr. Fox held both technical and commercial roles with Bruker and Shimadzu. He earned a bachelor of science degree in biochemistry from the University of Delaware and a Ph.D. in chemistry from Johns Hopkins University.

“This is a pivotal time in the life sciences industry with many life-saving breakthroughs on the edge of discovery, all while many laboratories are navigating unique challenges,” Dr. Fox stated. “At Beckman Coulter Life Sciences, our passion is solving customer problems. We will lead the way with customizable, sustainable solutions that accelerate and simplify complex workflows in service to our customers. Together, we’ll tackle global health challenges, revolutionize healthcare, and elevate patient care.”
 
Beckman Coulter Life Sciences has introduced several new solutions in 2024 to improve laboratory workflows, including the CytoFLEX nano Flow Cytometer to revolutionize nanoparticle analysis, the QbD1200+ Total Organic Carbon Analyzer to accelerate pharmaceutical and biopharmaceutical analysis, and the Biomek Echo One System for high-throughput genomic sample preparation. The company has also recently partnered with DLL Financial Solutions, a wholly owned subsidiary of Rabobank, to make financing options more accessible.
 
Beckman Coulter Life Sciences is a laboratory partner providing automation and innovation solutions for centrifugation, flow cytometry, genomics, particle analysis, and liquid handling workflows. Its technologies reduce manual laboratory processes and can provide greater speed, accuracy, and advanced analytics to accelerate answers with a guiding focus to improve patient care and enable discoveries. Beckman Coulter Life Sciences, part of the Danaher Corporation family of global science and technology companies, is headquartered in Indianapolis, Ind., with 11 operational hubs worldwide, and employs approximately 3,300 associates with more than 400,000 systems installed globally.